ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Blueprint Medicines
An internship role at Blueprint Medicines offering students the opportunity to gain experience in clinical operations within a biopharmaceutical environment. The program provides hands-on learning, mentorship, and exposure to industry practices in clinical trial management and medical research.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2011
Blueprint Medicines is a biotechnology company focused on developing targeted therapies for patients with cancer and rare diseases. The company uses precision medicine and genomics to design drugs that selectively inhibit disease-causing proteins, particularly kinase-driven cancers and systemic mastocytosis.
MSNSanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies
4 days ago
Yahoo FinanceBlueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
2 weeks ago
European Pharmaceutical ReviewBlueprint’s rare disease drug Ayvakit shows long-term benefit
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Blueprint Medicines.
InvestopediaBlueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
Jun 2, 2025
